Please ensure Javascript is enabled for purposes of website accessibility

EntreMed reports higher loss in 1Q

EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, reported financial results for the three months ended March 31, 2014.

EntreMed reported a net loss of $1.5 million, or 5 cents per diluted share, compared with a net loss of $1.1 million, or 5 cents per diluted share, for the year-ago period.

The company reported no revenue in either year.

EntreMed said the increased net loss for the 2014 period was primarily due to higher costs associated with its research and development operations in China, as well as additional costs related to corporate business development initiatives in 2014.